glp1
CagriSema tracker
Educational reference for CagriSema. Use it inside TrackPep to log doses, side effects, and rotation sites.
Half-life
—
Tmax
—
Category
glp1
Also known as: cagri-sema, cagrilintide-semaglutide
CagriSema is an investigational cagrilintide plus semaglutide combination.
Mechanism
A fixed-ratio combination of cagrilintide (an amylin analogue) and semaglutide (a GLP-1 receptor agonist).
Research summary
Investigational combination studied in the REDEFINE program for weight management and in type 2 diabetes. Regulatory status should be verified against current FDA announcements.
Educational summary of published research. Not dosing guidance or medical advice.
Sources
- CagriSema phase 3 (REDEFINE) publications · peer-reviewed clinical trial series (2025)It is a combination; PK is that of its components. See the cagrilintide and semaglutide entries.
TrackPep er en loggføringsapp. Den registrerer det du logger, og anbefaler eller beregner aldri mengder.